Full history for every metric is available with a Kvantra account
Lysogene S.A. (LYS.PA)
Key financial summary
Financials in EUR| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 4 | 13 | 13 | 4 |
| Operating profit | €m | -13 | |||||
| Net profit | €m | -7 | -18 | -11 | -3 | -5 | -14 |
| EPS reported | € | -0.81 | |||||
| Operating cashflow per share | € | -0.86 | |||||
| Capex per share | € | 0.02 | |||||
| FCF per share | € | -0.87 | |||||
| Free cash flow | €m | -15 | |||||
| Net debt | €m | -2 | |||||
| Book value equity | €m | -4 | |||||
| Book value per share | € | -0.26 | |||||
| Number of shares | m | 16.87 | |||||
| DPS (TTM paid) | € | 0.00 |
Financial summary
Financials in EUR| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | -7.37 | |||||
| P/S LTM | x | 8.65 | |||||
| P/FCF LTM | x | -2.19 | |||||
| EV/EBITDA LTM | x | -2.22 | |||||
| EV/Sales LTM | x | 7.99 | |||||
| Earnings Yield LTM | % | -42.37% | |||||
| FCF Yield | % | -45.65% | |||||
| Quality | |||||||
| ROE | % | 312.27% | |||||
| ROIC | % | -236.37% | |||||
| Operating margin | % | -356.23% | |||||
| Gross margin | % | 49.37% | |||||
| FCF/Sales | % | -394.75% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | -72.09% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -1.49 | |||||
| Net Debt/EBITDA | x | 0.18 | |||||
| EBIT/Net interest | x | -214.37 | |||||
| Net debt/market cap | % | -7.54% | |||||
| Net debt/Equity | x | 0.56 | |||||
| Gross debt/equity | x | -2.26 | |||||
Company overview
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Lysogene S.A. (LYS.PA)
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free